share_log

424B5: Prospectus

424B5: Prospectus

424B5：募资说明书
美股SEC公告 ·  07/26 13:23

Moomoo AI 已提取核心信息

60 Degrees Pharmaceuticals, Inc., listed on The Nasdaq Capital Market under the symbol 'SXTP', has announced an increase in the maximum aggregate gross sales price of its common stock to $2,190,416 through an At the Market Issuance Sales Agreement with WallachBeth Capital LLC. This increase, detailed in a prospectus supplement filed on July 26, 2024, amends previous registrations to allow for additional sales under the agreement. As of the filing date, 60 Degrees Pharmaceuticals has sold 7,525,879 shares for an aggregate gross sales price of $1,890,500.81. The company's outstanding common stock held by non-affiliates is valued at approximately $6,571,249, based on a share price of $0.351 as of June 7, 2024. The company adheres to the SEC's General Instruction I.B.6 of Form S-3, limiting sales to no more than one-third of their public float in a 12-month period, provided the public float remains below $75 million. Investors are advised to consider the risk factors outlined in the accompanying prospectus supplement and base prospectus, as well as other SEC filings.
60 Degrees Pharmaceuticals, Inc., listed on The Nasdaq Capital Market under the symbol 'SXTP', has announced an increase in the maximum aggregate gross sales price of its common stock to $2,190,416 through an At the Market Issuance Sales Agreement with WallachBeth Capital LLC. This increase, detailed in a prospectus supplement filed on July 26, 2024, amends previous registrations to allow for additional sales under the agreement. As of the filing date, 60 Degrees Pharmaceuticals has sold 7,525,879 shares for an aggregate gross sales price of $1,890,500.81. The company's outstanding common stock held by non-affiliates is valued at approximately $6,571,249, based on a share price of $0.351 as of June 7, 2024. The company adheres to the SEC's General Instruction I.B.6 of Form S-3, limiting sales to no more than one-third of their public float in a 12-month period, provided the public float remains below $75 million. Investors are advised to consider the risk factors outlined in the accompanying prospectus supplement and base prospectus, as well as other SEC filings.
60 Degrees Pharmaceuticals, Inc.，纳斯达克上市，股票代码为'SXTP'，已宣布通过一项与WallachBeth Capital LLC签订的市场发行协议，将其普通股的最大总售价上调至$2,190,416。这一增加的条款详见于2024年7月26日提交的招股说明书补充，修订了先前的注册，允许在协议下进行额外的股东减持。截至提交日期，60 Degrees Pharmaceuticals已售出了7,525,879股，总售价为$1,890,500.81。截至2024年6月7日，公司的未与关联方持有的普通股估值约为$6,571,249，基于股价为$0.351。该公司遵守SEC的《3号表格》I.b.6通用指令，在12个月内将销售额限制在公共流通股的三分之一以下，如果公共流通股仍然低于7500万。投资者应考虑随附的招股说明书补充、招股说明书以及其他SEC文件中概述的风险因素。
60 Degrees Pharmaceuticals, Inc.，纳斯达克上市，股票代码为'SXTP'，已宣布通过一项与WallachBeth Capital LLC签订的市场发行协议，将其普通股的最大总售价上调至$2,190,416。这一增加的条款详见于2024年7月26日提交的招股说明书补充，修订了先前的注册，允许在协议下进行额外的股东减持。截至提交日期，60 Degrees Pharmaceuticals已售出了7,525,879股，总售价为$1,890,500.81。截至2024年6月7日，公司的未与关联方持有的普通股估值约为$6,571,249，基于股价为$0.351。该公司遵守SEC的《3号表格》I.b.6通用指令，在12个月内将销售额限制在公共流通股的三分之一以下，如果公共流通股仍然低于7500万。投资者应考虑随附的招股说明书补充、招股说明书以及其他SEC文件中概述的风险因素。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间